A dual-targeted small-molecule photosensitizer with enhanced dual antitumor and anti-vascular effect for metastatic advanced prostate cancer photodynamic therapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Porphyrin and Phthalocyanine Chemistry
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (36)
Show source-provided references
1. Cancer statistics, 202310.3322/caac.21763 ↗
2. Overall survival advantage with radical prostatectomy for prostate cancer10.1200/JCO.2017.35.6_suppl.37 ↗
3. The evolution of fractionated prostate cancer radiotherapy10.1016/S0140-6736(19)31338-8 ↗
4. Hormonal therapy for prostate cancer10.1210/endrev/bnab002 ↗
5. A focus on focal therapy for prostate cancer10.1001/jamasurg.2021.3181 ↗
6. Cryoablation, high-intensity focused ultrasound, irreversible electroporation, and vascular-targeted photodynamic therapy for prostate cancer: a systemic review and meta-analysis10.1007/s10147-020-01847-y ↗
7. Oncologic photodynamic therapy: basic principles, current clinical status and future directions10.3390/cancers9020019 ↗
8. Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the advanced prostate cancer consensus conference 202210.1016/j.eururo.2022.11.002 ↗
9. Current therapy and drug resistance in metastatic castration-resistant prostate cancer10.1016/j.drup.2023.100962 ↗
10. Transcriptional mediators of treatment resistance in lethal prostate cancer10.1038/s41591-021-01244-6 ↗
11. Advanced prostate cancer: treatment advances and future directions10.1016/j.trecan.2020.04.010 ↗
12. Recent developments in the management of advanced prostate cancer10.6004/jnccn.2020.5021 ↗
13. The evolutionary history of lethal metastatic prostate cancer10.1038/nature14347 ↗
14. Supramolecular photosensitizers rejuvenate photodynamic therapy10.1039/C7CS00594F ↗
15. Clinical development of metal complexes as photosensitizers for photodynamic therapy of cancer10.1002/anie.202112236 ↗
16. Photodynamic therapy and anti-tumour immunity10.1038/nrc1894 ↗
17. New designs for phototherapeutic transition metal complexes10.1002/anie.201905171 ↗
18. Magnetic resonance and fluorescence imaging superparamagnetic nanoparticles induce apoptosis and ferroptosis through photodynamic therapy to treat colorectal cancer
19. Photodynamic therapy combined with immunotherapy: recent advances and future research directions10.1016/j.ccr.2023.215350 ↗
20. How to improve photodynamic therapy-induced antitumor immunity for cancer treatment?10.7150/thno.72465 ↗
21. Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
22. The unique features and promises of phthalocyanines as advanced photosensitisers for photodynamic therapy of cancer10.1039/C9CS00129H ↗
23. Photosensitizers for photodynamic therapy10.1002/adhm.201900132 ↗
24. A bright future for photosensitizers10.1038/s41557-020-0448-x ↗
25. Photodynamic therapy: a compendium of latest reviews10.3390/cancers13174447 ↗
26. Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site10.1186/1476-4598-12-7 ↗
27. Angiogenesis and vascular remodeling of vasa nervorum in locally advanced prostate cancer10.1200/JCO.2018.36.6_suppl.341 ↗
28. Angiogenesis in health and disease10.1038/nm0603-653 ↗
29. Antivascular therapy of cancer: DMXAA10.1016/S1470-2045(03)01018-0 ↗
30. Vascular-disrupting agents in oncology10.1517/13543784.2013.759557 ↗
31. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice10.1038/sj.bjc.6601606 ↗
32. A DNA/DMXAA/Metal–Organic framework activator of innate immunity for boosting anticancer immunity
33. The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression10.1080/2162402X.2017.1346765 ↗
34. Novel targeted photosensitizer as an immunomodulator for highly efficient therapy of T-cell acute lymphoblastic leukemia10.1021/acs.jmedchem.0c01072 ↗
35. An aromatase inhibitor in combination with Zinc(II) phthalocyanine for targeted therapy of post-menopausal breast cancer10.1016/j.dyepig.2022.110281 ↗
36. A monoamine oxidase-A inhibitor phthalocyanine conjugate for targeted photodynamic therapy and inhibition of prostate cancer metastasis in vitro10.1016/j.dyepig.2022.110717 ↗